Cyduct Diagnostics Inc Stock Price, News & Analysis

CYduct Diagnostics, Inc. (OTC PINK:CYDX) has provided a corporate outlook for 2023, emphasizing a commitment to advancing innovative healthcare products. In 2022, the company focused on enhancing its current offerings and initiating new product candidates. Key initiatives for 2023 include:

• Conducting clinical trials for B-FIRST™, a breast cancer risk assessment product.
• Developing a Point-of-Care proteomic device using patented nano sensor technology.
• Partnering with a leading biomedical engineering firm.
• Applying for an NIH grant for product development.

Overall, CYduct aims to enhance shareholder value while accelerating research and development in breast healthcare.

CYduct Diagnostics, Inc. (OTC PINK:CYDX) announced the completion of an audit by TPS Thayer LLC for its consolidated financial statements for the years ending June 30, 2022, and 2021. President Dominick Gatto expressed pride in achieving this milestone, highlighting the company's commitment to women's healthcare, particularly in breast health and wellness. The company aims to become a fully reporting entity as it continues to innovate and improve its technologies. Shareholders are encouraged to follow the company’s updates on social media.

CYduct Diagnostics, Inc. (CYDX) provided a corporate update emphasizing strategic developments in women's healthcare, particularly in breast health. The company aims to become fully reporting by early 2023, having retained TPS Thayer for auditing and appointed Anthony L.G. as legal counsel. Notable achievements include the acquisition of HHC Preferred LLC's noninvasive diagnostic device and a research agreement with Yale University for breast cancer biomarker detection. Upcoming initiatives focus on product development and partnerships, with a commitment to enhancing women's health and shareholder value.

CYduct Diagnostics, Inc. (CYDX) has joined BioCT, enhancing its presence within Connecticut's biosciences community. CEO Dominick Gatto expressed optimism about leveraging BioCT's resources to further the company's growth in women's healthcare, specifically focusing on breast health innovations. Established over 30 years ago, CYduct specializes in medical devices and procedural techniques for disease management. The company aims to utilize Connecticut's resources for strategic planning and product development.

CYduct Diagnostics, Inc. (OTC PINK:CYDX) announced on November 15, 2021, the appointment of Laura Anthony and her firm Anthony L.G., PLLC as corporate and securities counsel. CEO Dominick Gatto expressed optimism about working with a firm experienced in the needs of small to mid-sized publicly traded companies, emphasizing the importance of innovative legal strategies for the company's growth. CYduct focuses on innovations in women's healthcare, particularly in breast health, with a history of providing quality medical products for over 30 years.

CYduct Diagnostics, Inc. (OTC PINK:CYDX) reported its financial results for the fiscal year ending June 30, 2021. Despite challenges posed by the COVID-19 pandemic, the company completed its capital restructuring and initiated significant corporate milestones. CEO Dominick Gatto highlighted a strategic acquisition and a research agreement with Yale University, which are expected to enhance revenue potential. The firm aims to establish itself as a leader in the women's healthcare sector, focusing on intraductal breast health product lines to exceed historical revenue levels.

CYduct Diagnostics, Inc. (OTC PINK:CYDX) has announced the retention of TPS Thayer, LLC for audit services covering the years ended June 30, 2020, and 2021. This move accompanies a shift in the company's fiscal year end from December 31 to June 30. The firm, known for its expertise in financial services for publicly-held companies, is expected to complete the audit within 90 days. President Dominick Gatto highlighted that the acquisition of HALO technology has significantly increased revenue potential, emphasizing the importance of strengthening financial reporting.

CYduct Diagnostics (OTC PINK:CYDX) has successfully acquired the assets of HHC PREFERRED LLC, enhancing its capabilities in breast healthcare. The acquisition includes patented technology for a noninvasive device that collects nipple aspirate fluid (NAF), which is essential for proteomic analysis aimed at early breast cancer detection. This strategic move is expected to significantly improve yield rates of NAF extraction and solidify CYduct's position in the women's health market. Financial details of the agreement remain undisclosed.

CYduct Diagnostics (OTC PINK:CYDX) has entered a Sponsored Research Agreement with Yale University, effective April 1, 2021, to evaluate nanowire biosensor technology aimed at detecting breast cancer biomarkers. This one-year agreement includes exclusive options for worldwide licensing of the underlying technology. The research focuses on assessing breast health and risk screening, particularly for women with dense breast tissue. Financial details remain undisclosed.